AlloVir Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AlloVir stock.
View analyst ratings for AlloVir or view top-rated stocks.

Wall Street analysts have given AlloVir a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AlloVir wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

AlloVir is scheduled to release its next quarterly earnings announcement on Wednesday, September 1st 2021.
View our earnings forecast for AlloVir.

AlloVir, Inc. (NASDAQ:ALVR) released its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.10.
View AlloVir's earnings history.

4 brokerages have issued 1-year price targets for AlloVir's shares. Their forecasts range from $42.00 to $55.00. On average, they anticipate AlloVir's stock price to reach $49.25 in the next twelve months. This suggests a possible upside of 117.0% from the stock's current price.
View analysts' price targets for AlloVir or view top-rated stocks among Wall Street analysts.

Some companies that are related to AlloVir include Beam Therapeutics (BEAM), Recursion Pharmaceuticals (RXRX), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Sana Biotechnology (SANA), Kodiak Sciences (KOD), Abcam (ABCM), SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Bavarian Nordic A/S (BVNRY) and NanoString Technologies (NSTG).
View all of ALVR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), The Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).

(ALVR) raised $252 million in an initial public offering on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

AlloVir trades on the NASDAQ under the ticker symbol "ALVR."

AlloVir's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.64%), Redmile Group LLC (2.99%), Woodline Partners LP (1.81%), Alliancebernstein L.P. (1.69%), American International Group Inc. (1.55%) and Massachusetts Financial Services Co. MA (0.94%). Company insiders that own AlloVir stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Brett R Hagen, Diana Brainard, Edward Miller, John Robert Wilson and Juan Vera.
View institutional ownership trends for AlloVir.

ALVR stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, TCW Group Inc., Credit Suisse AG, and Massachusetts Financial Services Co. MA. Company insiders that have sold AlloVir company stock in the last year include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Brett R Hagen, Edward Miller, John Robert Wilson, and Juan Vera.
View insider buying and selling activity for AlloVir or view top insider-selling stocks.

ALVR stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Goldman Sachs Group Inc., Woodline Partners LP, Geode Capital Management LLC, American International Group Inc., Citigroup Inc., and Northern Trust Corp. Company insiders that have bought AlloVir stock in the last two years include Beek Jeroen B Van, and Diana Brainard.
View insider buying and selling activity for AlloVir or or view top insider-buying stocks.

Shares of ALVR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALVR stock can currently be purchased for approximately $22.70.

AlloVir has a market capitalization of $1.48 billion and generates $170,000.00 in revenue each year. The company earns $-69,780,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

AlloVir employs 53 workers across the globe.

The official website for AlloVir is www.allovir.com.

AlloVir is headquartered at 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142.

AlloVir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-433-2605 or via email at [email protected]